PRESS RELEASE : MagForce AG Successfully Completes Private Placement of New Shares

 
 DGAP-News: MagForce AG / Key word(s): Capital Increase 
MagForce AG Successfully Completes Private Placement of New Shares 
 
2020-12-15 / 13:20 
The issuer is solely responsible for the content of this announcement. 
 
*MagForce AG Successfully Completes Private Placement of New Shares * 
 
*- Placement of 1.165 million shares or 4.2 percent of the share capital* 
 
*- Gross proceeds of approx. EUR 4.7 million * 
 
*Berlin and Nevada, December 15, 2020* - MagForce AG (Frankfurt, Scale, 
XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the 
field of nanomedicine focused on oncology, announced today that the 
Management Board, with approval of the Supervisory Board, has resolved and 
successfully completed an increase the Company's share capital by way of a 
partial exercise of authorized capital under exclusion of shareholders' 
subscription rights in the amount of 1,165,000 EUR by issuing 1,165,000 new 
ordinary bearer shares with no-par value (Stückaktien), each with a notional 
value of EUR 1.00, against cash contributions (the "New Shares"). 
 
The New Shares were allocated at a placement price of 4.00 EUR per share in 
a private placement. The majority of the New Shares were subscribed by 
Apeiron Investment Group Ltd. and by MagForce's CEO, Dr. Ben Lipps. 
 
_"2021 is set to be a decisive year as we hope to see the successes of our 
two-pronged strategy that we implemented for bringing our NanoTherm therapy 
system to benefit brain tumor patients in Europe as well as prostate cancer 
patients in the US. We are grateful for the trust that our long standing 
investors and also new shareholders place in our innovative technology," 
_*said Dr. Ben Lipps, Chief Executive Officer of MagForce AG and MagForce 
USA, Inc.* 
 
The Company intends to use the net proceeds from the Capital Increase to 
further implement its growth strategy and to strengthen the balance sheet: 
 
*In Europe,* MagForce had made significant progress in its roll-out strategy 
to bring its innovative NanoTherm therapy system to brain tumor patients 
which *is *now been impressively reflected in the treatment figures. The 
official opening of the latest NanoTherm therapy treatment center in 
Germany, at the Hufeland clinic in Mühlhausen, which was announced earlier 
this week, marks the fourth clinic in Europe offering MagForce's technology 
for the commercial treatment of brain tumors. MagForce is also planning 
further installations of NanoActivator devices as part of their European 
rollout strategy in partner hospitals in other European countries and also 
anticipates another NanoTherm treatment center in Germany. 
 
*In the US,* MagForce is currently completing stage 2a of its U.S. focal 
prostate cancer treatment study. Treatment results in the current stage of 
the study, with a streamlined procedure, show only minimal treatment-related 
side effects that are tolerable and similar to those of biopsies. The 
ablation analysis showed a very well-defined ablation and cell death in the 
area of the nanoparticle deposit, as observed in previous preclinical 
studies. Start of the final stage of the study, Stage 2b, is expected to 
begin in early 2021. While the study is being completed, MagForce will 
already begin preparations for commercialization, which is anticipated to 
start in mid or the second half of 2021. 
 
*About MagForce AG and MagForce USA, Inc.* 
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange 
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. 
is a leading medical device company in the field of nanomedicine focused on 
oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted 
treatment of solid tumors through the intratumoral generation of heat via 
activation of superparamagnetic nanoparticles. 
 
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the 
therapy and have received EU-wide regulatory approval as medical devices for 
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and 
NanoActivator are trademarks of MagForce AG in selected countries. 
 
*For more information, please visit: www.magforce.com [1] 
Get to know our Technology: video (You Tube) [2] 
Stay informed and subscribe to our mailing list [3]* 
 
*Press- and investor contact information:* 
 
Barbara von Frankenberg 
VP Communications & Investor Relations 
T [phone] 
M [e-mail] 
 
_Disclaimer _ 
 
This release may contain forward-looking statements and information which 
may be identified by formulations using terms such as "expects", "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or 
"will". Such forward-looking statements are based on our current 
expectations and certain assumptions, which may be subject to a variety of 
risks and uncertainties. The results actually achieved by MagForce AG may 
substantially differ from these forward-looking statements. MagForce AG 
assumes no obligation to update these forward-looking statements or to 
correct them in case of developments, which differ from those, anticipated. 
 
2020-12-15 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     MagForce AG 
             Max-Planck-Straße 3 
             12489 Berlin 
             Germany 
Phone:       [phone] 
Fax:         [phone] 
E-mail:      [e-mail] 
Internet:    www.magforce.com 
ISIN:        DE000A0HGQF5 
WKN:         A0HGQF 
Indices:     Scale 30 
Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt 
             (Scale), Stuttgart, Tradegate Exchange 
EQS News ID: 1155314 
 
End of News DGAP News Service 
 
1155314 2020-12-15 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=1155314&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=1155314&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=1155314&site_id=vwd&application_name=news

(END) Dow Jones Newswires

December 15, 2020 07:20 ET (12:20 GMT)